WallStreetZenWallStreetZen

NASDAQ: ESPR
Esperion Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Esperion Therapeutics revenue was $303.80M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $87.3M, up 6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ESPR annual revenue was $332.3M, with 185.7% growth year-over-year.

ESPR past revenue growth

How has ESPR's revenue growth performed historically?

Company
2.83%
Industry
2.51%
Market
22.91%
ESPR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ESPR's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ESPR's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ESPR revenue history

Current Revenue
$303.8M
Current Earnings
-$105.8M
Current Profit Margin
-34.8%

Be the first to know when ESPR announces revenue.

ESPR Revenue History By Year

ESPR Yearly RevenueESPR RevenueESPR ChangeESPR Revenue Growth
2024-12-31$332.31M$215.98M+185.66%
2023-12-31$116.33M$40.86M+54.14%
2022-12-31$75.48M-$2.97M-3.79%
2021-12-31$78.45M-$149.10M-65.52%
2020-12-31$227.55M$79.18M+53.37%
2019-12-31$148.36MN/AN/A
2018-12-31$0.00N/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00N/AN/A
2011-12-31$0.00N/AN/A

1 of 1

Esperion Therapeutics Revenue FAQ

What was ESPR's revenue last quarter?

On Invalid Date, Esperion Therapeutics (NASDAQ: ESPR) reported Q3 2025 revenue of $87.31 million up 69.1% year over year. In the same quarter last year, Esperion Therapeutics's revenue was $51.63 million.

What was Esperion Therapeutics's revenue in 2024?

Esperion Therapeutics's annual revenue for the twelve months ending Dec 31, 2024 was $332.31 million, a 185.66% increase year over year.

How much does Esperion Therapeutics make in a day?

Based on Esperion Therapeutics annual revenue for the past five years, ESPR makes an average of $454,858.63 per day.

What was Esperion Therapeutics's annual revenue growth in the past year?

As of Q4 2025, Esperion Therapeutics's revenue has grown 2.83% year over year. This is 0.31 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 2.51%. Esperion Therapeutics's revenue in the past year totaled $303.80 million.

How much does Esperion Therapeutics make in a year?

Esperion Therapeutics's revenue by year for the past five years is:
  • Esperion Therapeutics's revenue for the twelve months ending Dec 31, 2024 was $332.31 million, a 185.66% increase year over year.
  • Esperion Therapeutics's annual revenue for Dec 31, 2023 was $116.33 million, a 54.14% increase from 2022.
  • Esperion Therapeutics's annual revenue for 2022 was $75.48 million, a 3.79% decrease from 2021.
  • Esperion Therapeutics's annual revenue for 2021 was $78.45 million, a 65.52% decrease from 2020.
  • Esperion Therapeutics's annual revenue for 2020 was $227.55 million, a 53.37% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.